# Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

> **NCT06155383** · PHASE2 · RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** oxaliplatin
- **DRUG:** Disitamab Vedotin
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT06155383
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-27
- **Primary completion:** 2025-01-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06155383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06155383, "Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06155383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*